Gossamer Bio Inc (GOSS) Stock Price, Quote & News

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to devel...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 684 1300

Website: www.gossamerbio.com

Address:

3115 Merryfield Row, Suite 120, San Diego, United States

Finnish_boy Sep. 10 at 8:58 AM

$GOSS i am super bullish. Much volatitily during this and next week but this will be very likely multibagger. PDUFA run up PT $0.5 and if approval >>$1.

0 · Reply

Partyflags Sep. 10 at 8:38 AM

$GOSS

0 · Reply

P2W6zero Sep. 10 at 8:06 AM

$GOSS your welcome.

0 · Reply

Daniii23 Sep. 10 at 7:49 AM

$GOSS btchss

0 · Reply

DocKnocks Sep. 10 at 4:21 AM

$GOSS 1 for 80 🤢

0 · Reply

hiddenwolf Sep. 10 at 2:44 AM

$GOSS 1 to 80 reverse split. Not much to say passed that

0 · Reply

Dellbell Sep. 10 at 2:36 AM

$GOSS why most of the people say its a scam

0 · Reply

Lenano Sep. 10 at 2:23 AM

$GOSS first reverse split I go through what happens to my options that I own. I owe a couple one expires 18th of this month the rest the next two years.

0 · Reply

Bullishontherize Sep. 10 at 1:35 AM

$GOSS On a brighter note, at least we can write calls now.

0 · Reply

AlexRo777 Sep. 10 at 1:10 AM

$GOSS if it jumps to 0.3 before the RS, i will be the happiest man alive

1 · Reply

Gossamer Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

2026-09-09T13:11:04.000Z - 21 hours ago

Gossamer Bio announces 1-for-80 reverse stock split

Sep 9, 2026, 9:00 AM EDT - 21 hours ago

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Sep 8, 2026, 8:00 AM EDT - 1 day ago

Gossamer Bio Slides: Corporate presentation

Sep 4, 2026, 8:00 AM EDT - 5 days ago

Gossamer Bio to Present at Cantor Global Healthcare Conference

Sep 3, 2026, 8:00 AM EDT - 6 days ago

Gossamer Bio Proxy statement: Proxy filing

2026-08-21T12:05:19.000Z - 19 days ago

Gossamer Bio announces upt to $250M structured private placement

Aug 21, 2026, 8:00 AM EDT - 19 days ago

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

2026-08-16T14:14:17.000Z - 24 days ago

Gossamer Bio reports Q2 EPS (8c), consensus (12c)

2026-08-16T13:26:28.000Z - 24 days ago

Gossamer Bio price target lowered to $4 from $15 at Piper Sandler

Aug 13, 2026, 4:01 PM EDT - 27 days ago

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 7:00 AM EDT - 27 days ago

Gossamer Bio Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 27 days ago

Gossamer Bio Earnings release: Q2 2026

2026-07-27T22:00:09.000Z - 6 weeks ago

Gossamer Bio upgraded to Outperform from Market Perform at Leerink

Jul 27, 2026, 8:00 AM EDT - 6 weeks ago

Gossamer Bio Transcript: Investor update

Jul 27, 2026, 8:00 AM EDT - 6 weeks ago

Gossamer Bio Press release: Investor update

2026-07-27T11:10:56.000Z - 6 weeks ago

Gossamer announces FDA regulatory update, reacquisition of Seralutinib rights

Jul 27, 2026, 7:00 AM EDT - 6 weeks ago

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

2026-07-01T13:15:31.000Z - 2 months ago

Gossamer Bio announces determination of conversion rate for senior secured notes

Jul 1, 2026, 9:00 AM EDT - 2 months ago

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

2026-06-25T16:35:28.000Z - 2 months ago

Gossamer Bio price target lowered to $2 from $5 at H.C. Wainwright

2026-06-17T12:17:12.000Z - 2 months ago

Gossamer Bio announces final tender results

Jun 17, 2026, 8:00 AM EDT - 2 months ago

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Jun 9, 2026, 8:00 AM EDT - 3 months ago

Gossamer Bio Proxy statement: Proxy filing

2026-06-03T13:13:56.000Z - 3 months ago

Gossamer Bio announces early tender results, early settlement of solicitation

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

2026-06-02T13:07:00.000Z - 3 months ago

Gossamer Bio announces extension of early tender date for exchange offer

Jun 2, 2026, 8:00 AM EDT - 3 months ago

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

2026-05-29T09:38:46.000Z - 3 months ago

Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims

2026-05-20T20:11:13.000Z - 3 months ago